Over the first 3 months, the PSA exhibited a small decrease to 339.7 ng/mL; after 6 months of treatment, the PSA went down to 243.7 ng/mL, but the laboratory data revealed a worsening of renal function with a blood urea nitrogen level of 60 mg/dL, a creatinine level of 3.5 mg/dL, and a creatinine clearance of 19.64 mL/min (stage 4 CKD). Here, KLK3 is linked to chronic kidney disease.